ClinicalTrials.Veeva
Menu

Find clinical trials for Adenocarcinoma in Barcelona, CT

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Carcinoma
Cancer
Pancreatic Cancer
Colorectal Cancer
Stomach Cancer
Esophageal Cancer
Non-Small-Cell Lung Carcinoma

Adenocarcinoma trials near Barcelona, CT, ESP:

Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)

with HER2-positive gastric or gastro-esophageal junction (GEJ) adenocarcinoma who have progressed on or after a trastuzumab-containing regim...

Active, not recruiting
Gastric Cancer, Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
Drug: Ramucirumab
Drug: Paclitaxel

Phase 3

Daiichi Sankyo
Daiichi Sankyo

Barcelona, Spain and 155 other locations

A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015) (TroFuse-015)

(TPC) in participants with advanced/metastatic gastroesophageal adenocarcinoma. The primary hypothesis of this study is sacituzumab tirumote...

Enrolling
Gastroesophageal Cancer
Drug: Rescue medication
Drug: Supportive care measures

Phase 3

Merck Sharp & Dohme (MSD)
Merck Sharp & Dohme (MSD)

Barcelona, Spain and 113 other locations

The HistoSonics Edison™ System for Treatment of Pancreatic Adenocarcinoma Using Histotripsy (GANNON)

The purpose of this trial is to evaluate the safety of the HistoSonics Edison System for the destruction of pancreatic adenocarcinomas using...

Enrolling
Adenocarcinoma of the Pancreas
Pancreas Cancer
Device: HistoSonics Edison™ System for the treatment of pancreatic adenocarcinoma using histotripsy
HistoSonics

Barcelona, Spain

Status recently updated

EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal Adenocarcinoma

The PANOVA-4 study is designed to evaluate the safety and efficacy of Tumor Treating Fields (TTFields) therapy together with atezolizumab, gemcitabin...

Enrolling
Active, not recruiting
Metastatic Pancreatic Ductal Adenocarcinoma
Drug: Atezolizumab
Drug: Gemcitabine

Phase 2

NovoCure
NovoCure

Barcelona, Spain and 4 other locations

Safety and Efficacy of Mitazalimab in Combination With Chemotherapy in Pancreatic Cancer Patients (OPTIMIZE-1)

Phase 1b/2 study to assess the safety and efficacy of mitazalimab in combination with chemotherapy in patients with metastatic pancreatic ductal adenocarcinoma...

Active, not recruiting
Metastatic Pancreatic Ductal Adenocarcinoma
Biological: CD40 agonist mitazalimab in combination with chemotherapy

Phase 1, Phase 2

Alligator Bioscience

Barcelona, Spain and 13 other locations

Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

and immunogenicity of novel combination therapies in participants with locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma...

Enrolling
Gastric Cancer
Drug: AZD0901
Drug: Capecitabine

Phase 2

AstraZeneca
AstraZeneca

Barcelona, Spain and 42 other locations

A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

combinations in participants with metastatic Pancreatic Ductal Adenocarcinoma (PDAC).Two cohorts will be enrolled in parallel in this study:...

Active, not recruiting
Pancreatic Adenocarcinoma
Drug: Gemcitabine
Drug: Bevacizumab

Phase 1, Phase 2

Roche
Roche

Barcelona, Spain and 26 other locations

A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW)

The purpose of this study is to evaluate the efficacy of zolbetuximab plus capecitabine and oxaliplatin (CAPOX) compared with placebo plus CAPOX (as...

Active, not recruiting
Metastatic Gastric Adenocarcinoma or Cancer
Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer
Drug: placebo
Drug: oxaliplatin

Phase 3

Astellas
Astellas

Barcelona, Spain and 164 other locations

A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body (STAR-221)

first-line treatment of participants with locally advanced unresectable or metastatic gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma...

Active, not recruiting
Advanced Upper Gastrointestinal Tract Adenocarcinoma
Drug: Domvanalimab
Drug: Zimberelimab

Phase 3

Arcus Biosciences
Arcus Biosciences

Barcelona, Spain and 203 other locations

A Study of Evorpacept (ALX148) in Patients with Advanced HER2+ Gastric Cancer (ASPEN-06)

of Evorpacept (ALX148) in Combination With Trastuzumab, Ramucirumab, and Paclitaxel in Patients With Advanced HER2-overexpressing gastric/GEJ adenocarcinoma...

Enrolling
Gastroesophageal Junction Adenocarcinoma
Gastric Adenocarcinoma
Drug: Trastuzumab
Drug: Paclitaxel

Phase 2, Phase 3

ALX Oncology

Barcelona, Spain and 83 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2024 Veeva Systems